Update shared on 26 Nov 2025
Fair value Increased 3.97%Analysts have raised their price target for BrightSpring Health Services from $38.25 to $39.77. This adjustment is supported by expectations for sustained revenue growth and expanding opportunities in drug contracts and provider services.
Analyst Commentary
Recent research notes highlight both the strengths and potential challenges facing BrightSpring Health Services. Analysts are generally optimistic about the company’s positioning, yet they caution that execution risks and market factors should not be overlooked.
Bullish Takeaways- Bullish analysts point to a strong growth trajectory, supported by opportunities to sign additional limited distribution drug contracts.
- The company is expected to benefit from generic drug conversions, which could help enhance profitability in the coming years.
- Expansion in Provider Services is seen as an important avenue for incremental growth and revenue diversification.
- Expectations of sustained EBITDA growth, projected at over 12% annually for the next three years, support higher valuation targets for the stock.
- Analysts note that the company may face challenges in executing its growth strategy, particularly in a highly regulated healthcare environment.
- The outlook depends on the company’s ability to win and integrate new drug contracts, which may introduce variability in near-term results.
- Increasing competition across drug distribution and provider services could impact market share and margin expansion opportunities.
What's in the News
- BrightSpring Health Services completed a follow-on equity offering and raised approximately $431.73 million through the sale of 15 million shares of common stock at $28.78 per share (Key Developments).
- The company raised its fiscal year 2025 consolidated earnings guidance, projecting revenues between $12.4 billion and $12.7 billion. Pharmacy segment revenues are expected to grow by up to 27.9% (Key Developments).
- Preliminary results for the third quarter of 2025 indicate total revenues of $3.33 billion and net income of $55.24 million, with diluted earnings per share of $0.26 (Key Developments).
- BrightSpring Health Services was recently added to several S&P indices, including the S&P 1000, S&P Composite 1500, and S&P 600 Health Care indexes (Key Developments).
- Lock-up agreements covering options, restricted stock units, and common stock will expire on December 20, 2025, following a 61-day lock-up period for directors, officers, and selling stockholders (Key Developments).
Valuation Changes
- Consensus Analyst Price Target has increased modestly from $38.25 to $39.77.
- Discount Rate has risen slightly from 6.78% to 6.96%.
- Revenue Growth expectations have edged up from 12.33% to 12.43%.
- Net Profit Margin has decreased marginally from 2.41% to 2.40%.
- Future P/E ratio is projected to move up from 23.19x to 23.91x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.